United Therapeutics (UTHR) Beats Q3 Earnings Estimates

Core Insights - United Therapeutics reported quarterly earnings of $7.16 per share, exceeding the Zacks Consensus Estimate of $6.89 per share, and up from $6.39 per share a year ago, representing an earnings surprise of +3.92% [1] - The company posted revenues of $799.5 million for the quarter ended September 2025, which was below the Zacks Consensus Estimate by 2.24%, but an increase from $748.9 million year-over-year [2] - United Therapeutics shares have increased approximately 17.7% year-to-date, slightly outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The future performance of United Therapeutics' stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is $6.57, with projected revenues of $792.76 million, and for the current fiscal year, the EPS estimate is $26.67 on revenues of $3.2 billion [7] Industry Context - The Medical - Drugs industry, to which United Therapeutics belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The correlation between near-term stock movements and earnings estimate revisions suggests that tracking these revisions can provide insights into stock performance [5]